Ultragenyx Pharmaceutical (RARE) Current Assets (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Current Assets data on file, last reported at $657.0 million in Q1 2026.

• On a quarterly basis, Current Assets fell 6.03% year-over-year to $657.0 million in Q1 2026; TTM through Mar 2026 was $657.0 million, a 6.03% decrease from a year earlier, with the FY2025 full-year figure at $951.0 million, up 16.4% from the prior year.
• Current Assets for Q1 2026 stood at $657.0 million, down from $951.0 million in the prior quarter.
• Over the last five years, Current Assets for RARE reached as high as $1.0 billion in Q3 2022 and fell as low as $596.0 million in Q1 2024.
• Historically, Current Assets has averaged $760.6 million across 5 years, with a median of $719.8 million in 2025.
• Across the five-year window, Current Assets slumped 40.83% in 2023 and surged 37.39% in 2024, its largest moves.
• Year by year, Current Assets stood at $883.9 million in 2022, then declined by 17.16% to $732.2 million in 2023, then increased by 11.58% to $817.0 million in 2024, then gained by 16.4% to $951.0 million in 2025, then tumbled by 30.91% to $657.0 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $657.0 million in Q1 2026, $951.0 million in Q4 2025, and $643.2 million in Q3 2025.